marketnews

Unveiling the Power of ALAUNOS Therapeutics: A Look into their Revolutionary HUNTR TCR Discovery Platform at the Society for Immunotherapy of Cancer’s 2022 Annual Meeting

Alaunos Therapeutics to Present Data High… Data supports high-throughput screening process to identify neoantigen-reactive TCRs Exclusive ownership of discovered KRAS mutation-reactive TCRs hunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company…

Read More

Unstoppable Growth: Durable Medical Equipment (DME) Market Set to Surpass US$261 Billion by 2027, Reveals TMR Study

Increasing Demand from Home Healthcare Settings Boost Adoption of Products in the Global Durable Medical Equipment (DME) Market Wilmington, Delaware, United States, Nov. 03, 2022 (GLOBE NEWSWIRE) Transparency Market Research Inc. – Growing number of government authorities and committees, as well as private organizations are launching various programs and initiatives to offer financial support. The…

Read More

RLAXX TV Partners with Magnite’s SSP to Boost Ad Strategy Across Europe

German-based FAST and AVOD service expands its programmatic OTT advertising capabilities BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising platform, has entered into a strategic collaboration with rlaxx TV, an ad-supported VOD service available in 26 countries. As part of the deal, rlaxx TV will utilize Magnite’s…

Read More

iRhythm Technologies Reacts to Medicare’s 2023 Physician Fee Schedule: What You Need to Know!

iRhythm Technologies Reacts to Medicare’s 2023 Physician Fee Schedule: What You Need to Know! Description: SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today provided commentary on the recently released Centers for Medicare and…

Read More

Innovative and Professional: Outlook Therapeutics Receives FDA Acceptance for ONS-5010 as Wet AMD Treatment

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Retinal Diseases Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved…

Read More